

SAVE THE DATE

- Cancer Biology
- Cancer Evolution
- Early Cancer Detection
- Minimal Residual Disease (MRD)
- Disease Monitorization and RECIST-ctDNA
- Liquid Biopsy in Clinical Trials
- Multimodal Data Integration
- Emerging Technologies and Biomarkers
- Cancer Immunotherapy

VISIT THE WEBSITE 



15th International
Congress on

LIQUID BIOPSY 2027

"Former ISMRC"

12 - 14 MAY 2027

PALMA DE MALLORCA

Co-chairs:

Rodrigo Toledo
Catherine Alix-Panabières
Klaus Pantel

Venue:

Auditorium Palma de Mallorca
Av. de Gabriel Roca, 18, Ponent

Organised by:



EUROPEAN
LIQUID BIOPSY
SOCIETY

PRELIMINARY SCIENTIFIC PROGRAMME

WEDNESDAY, MAY 12 2027

07:30 REGISTRATION

09:00-09:15 OPENING REMARKS

09:15-10:50 SESSION 1. CANCER BIOLOGY

09:15-09:40 **Characterizing extracellular vesicle-mediated genomic, transcriptomic and proteomic intercellular communication.**

Héctor Peinado

Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

09:40-10:05 **Metabolic rewiring driving metastasis formation.**

Dr. Sarah-Maria Fendt

VIB Center for Cancer Biology, KU Leuven, Belgium

10:05-10:30 **Gut dysbiosis is a risk factor in immuno-oncology.**

Dr. Laurence Zitvogel

Gustave Roussy, Université Paris Saclay, Paris, France

10:30-10:40 **Selected Oral Communication 1**

10:40-10:50 **Selected Oral Communication 2**

10:50 – 11:30 COFFEE BREAK · POSTER VIEWING · NETWORKING

11:30-13:00 SESSION 2. CANCER EVOLUTION

11:30-11:55 **Tracking cancer evolution and designing disease interception using ultrasensitive ctDNA analysis.**

TBC

11:55-12:20 *Slot reserved to Liquid Biopsy Hot Topic*

12:20-12:45 **The role of phenotypic diversity and functional networks of CTC clusters during metastatic spread.**

Dr. Frédéric Thomas

Centre national de la recherche scientifique, Paris, France

12:45-12:55 **Selected Oral Communication 3**

12:55-13:05 **Selected Oral Communication 4**

13:05-14:30 LUNCH BREAK · POSTER SESSION · NETWORKING

14:30-16:30 SESSION 3. EMERGING TECHNOLOGIES AND BIOMARKERS

14:30-14:55 **Title TBC**

Dr. George A. Calin

UT MD Anderson, Houston, Texas, USA

14:55-15:20	TCR repertoire and longitudinal TCR-sequencing as a blood biomarker for patients treated with immunotherapy. Dr. Holger Heyn Centro Nacional de Análisis Genómico, Barcelona, Spain
15:20-15:45	Cerebrospinal Fluid for Brain Tumor Characterization and Monitoring Dr. Joan Seoane Vall d'Hebron Institute of Technology, Barcelona, Spain
15:45-16:10	Deciphering prostate cancer dynamics using extracellular vesicles. Francesca Demicaelis University of Trento, Italy
16:10-16:20	Selected Oral Communication 5
16:20-16:30	Selected Oral Communication 6
16:30-18:05	SESSION 4. EARLY CANCER DETECTION
16:30-16:55	Early detection of circulating mutations. Dr. Nickolas Papadopoulos Johns Hopkins University School of Medicine, New York, USA
16:55-17:20	New technologies for enhanced ctDNA detection. Dr. Viktor A. Adalsteinsson Gerstner Center for Cancer Diagnostics, Broad Institute of MIT, Harvard, Cambridge, Massachusetts, USA
17:20-17:45	Deciphering methylation profiles from plasma-based ctDNA for early tumor detection. Dr. Daniel de Carvalho Princess Margaret Cancer Center, Toronto, Canada
17:45-17:55	Selected Oral Communication 7
17:55-18:05	Selected Oral Communication 8

18:05 -19:15 POSTER SESSION AND NETWORKING

21:00 WELCOME RECEPTION

THURSDAY, MAY 13 2027

09:00-10:10 SESSION 5. MINIMAL RESIDUAL DISEASE

09:00-09:25 Updates on the PANCAID and GUIDE.MRD projects: current status and future perspectives
 Dr. Klaus Pantel
 Institute of Tumour Biology and University Medical Centre Hamburg-Eppendorf, Germany

09:25-09:50	ctDNA-MRD testing to guide adjuvant therapy in early-stage colorectal cancer Dr. Clara Montagut Hospital del Mar, Barcelona, Spain
09:50-10:00	Selected Oral Communication 9
10:00-10:10	Selected Oral Communication 10

10:10 – 10:40 COFFEE BREAK AND POSTER VIEWING - NETWORKING

10:40-12:50 SESSION 6. CLINICAL TRIALS

10:40-11:05	CT-scan RECIST vs ctDNA-RECIST in advanced lung cancer treatment with first-line immunotherapy: the PRELUCA study Dr. Malene Støchkel Frank Zealand University Hospital, Roskilde, Denmark
11:05-11:30	Incorporation of liquid biopsy in randomized clinical trials: past, present, and future. Dr. Silvia Marsoni IFOM Istituto Fondazione di Oncologia Molecolare ETS, Milano, Italy
11:30-11:55	Recent advances in ctDNA-guided bladder cancer management: lessons learned and incorporation into clinical guidelines Dr. Lars Dyrskjød Department of Clinical Medicine, Aarhus University, Denmark
11:55-12:20	Slot reserved to Liquid Biopsy Hot Topic
12:20-12:30	Selected Oral Communication 11
12:30-12:40	Selected Oral Communication 12
12:40-12:50	Selected Oral Communication 13

12:50-14:15 LUNCH AND POSTER SESSION – NETWORKING

14:15-15:25 SESSION 7. IMMUNOTHERAPY

14:15-14:40	The Next Generation of Liquid Biopsy: Multi-Omics for Precision Immuno-Oncology Dr. Catherine Alix-Panabières Centre Hospitalier Universitaire de Montpellier, France
14:40-15:05	The search for the ideal tumor-blood biomarker for Cancer Immunotherapy Dr. Paul Hofman Liquid Biopsy Centre, Nice, France
15:05-15:15	Selected Oral Communication 14

15:15-15:25	Selected Oral Communication 15
15:25-17:25	SESSION 8. DISEASE MONITORIZATION AND RECIST ctDNA
15:25-15:50	Use of real time ctDNA to guide therapy switch Dr. Caroline Dive Cancer Research UK National Biomarker Centre, Manchester, UK
15:50-16:15	Can we ctDNA-RECIST? Lessons from ongoing randomized interventional trials. Dr. Karen-Lise Garm Spindler Aarhus University Hospital, Denmark
16:15-16:40	Multimodal ctDNA derivatives for RECIST-ctDNA in the context of early clinical trials. Dr. Rodrigo Toledo Vall d'Hebron Institute of Oncology, Barcelona, Spain
16:40-17:05	Beyond mutation-based ctDNA for assessing therapy response and disease monitoring Dr. Julia Burnier McGill University Health Centre, Montreal, Canada
17:05-17:15	Selected Oral Communication 16
17:15-17:25	Selected Oral Communication 17

17:25-18:45 POSTER SESSION - NETWORKING

20:00 GALA DINNER

FRIDAY, MAY 14 2027

08:45 -09:30	SESSION 9. LATEST DEVELOPMENTS (Diamond & Platinum Sponsors)
08:45-09:00	Lecture – TBD (Technologies/Biomarkers)
09:00-09:15	Lecture – TBD (Neo Adj, Adj)
09:15-09:30	Lecture – TBD
09:30-10:40	SESSION 10. MULTIMODAL LBx DATA INTEGRATION
09:30-09:55	AI for integrating multimodal liquid biopsy into routine clinical practice Dr. Nuria Malats Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

09:50-10:20 **TCR repertoire from cell-free DNA: a new multimodal liquid biopsy component**
Dr. Trevor J. Pugh
Ontario Institute Cancer Research, Canada

10:20-10:30 **Selected Oral Communication 18**

10:30-10:40 **Selected Oral Communication 19**

10:40 – 11:10 COFFEE BREAK

11:10-12:20 SESSION 11. IMMUNOTHERAPY

11:10-11:35 **Plasma-based ctDNA fragmentomics for predicting response to immune checkpoint inhibitors**

Dr. Valsamo Anagnostou

Johns Hopkins University School of Medicine, Baltimore, USA

11:35-12:00 **Multimodal liquid biopsy biomarkers for cancer immunotherapy**

Dr. Rafael López

Complejo Hospitalario Universitario de Santiago de Compostela, Spain

12:00-12:10 **Selected Oral Communication 20**

12:10-12:20 **Selected Oral Communication 21**

12:20-13:20 SESSION 12. REGULATORY & REIMBURSEMENT

13:20-13:30 Young Investigator Awards

13:30-13:45 Concluding remarks

Secretaría técnica



📍 Barcelona · Madrid

☎ 93 451 17 24

✉ info@tacticsmd.net

🌐 www.tacticsmd.net